De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate
Article in Advances in Therapy (June 2024)
The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.
Article in Advances in Therapy (June 2024)
Article in ACS Applied Materials & Interfaces (February 2024)
Preprint in Research Square (February 2024)